Clinical Trial

ENGAGE: Virtual Reality-based Psychotherapy for Negative Symptoms in Schizophrenia

Study acronym: ENGAGE
Completed
View on ClinicalTrials.gov →
Summary
The primary goal of this pilot study is to examine the feasibility and acceptability of a new Virtual Reality-based intervention against negative symptoms in schizophrenia spectrum disorders (SSD). The main questions it aims to answer are: 1. Is Virtual Reality-based therapy a feasible and acceptable treatment for negative symptoms in SSD? 2. Are there indications that the treatment is effective in reducing negative symptoms, improving daily functioning, and enhancing quality of life? Researchers will compare the new Virtual Reality-based treatment to standard psychiatric care to evaluate therapy effectiveness. Participants will be allocated to receive either 10 sessions of Virtual Reality-based therapy or Treatment as usual. All participants will undergo a thorough assessment at baseline and at follow-up after 12 weeks.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-26; most recent amendment 2026-01-08.
Status change: Active, Not Recruiting → Completed 2026-01-08
Status change: Recruiting → Active, Not Recruiting 2025-09-04
Trial Details
NCT Number NCT06993831
Lead Sponsor Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Collaborators: Glostrup University Hospital, Copenhagen
Conditions Schizophrenia Spectrum Disorders, Negative Symptoms in Schizophrenia
Enrollment 30 participants
Start Date 2024-12-09
Primary Completion 2026-01-07 (estimated)
Study Completion 2026-01-07 (estimated)
Updated on ClinicalTrials.gov 2026-01-09